Biocartis announced an expansion of its collaboration with Merck Serono Middle East and Merck Saudi Ltd., both affiliates of Merck KGaA ("Merck"). The collaboration aims to improve patient access to RAS biomarker testing in the Middle East and North Africa (MEA) region. Colorectal cancer (CRC) is the third most common cancer worldwide, with an estimated incidence of more than 1.9 million new cases annually. RAS biomarker testing is cumbersome and not readily available in all parts of the world. Due to the ease-of-use of the Biocartis Idylla Platform, the Tests can be deployed in any user setting and in turn aid patient access to biomarker testing globally.
